Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

IInhibitor Therapeutics, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
I

Inhibitor Therapeutics, Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting
    Sep 8, 2026Inhibitor Therapeutics, Inc. (INTI) Press Releases
  • Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome
    Mar 31, 2026Inhibitor Therapeutics, Inc. (INTI) Press Releases
  • Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan
    Aug 22, 2024Inhibitor Therapeutics, Inc. (INTI) Press Releases
  • Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board
    Dec 19, 2023Inhibitor Therapeutics, Inc. (INTI) Press Releases
  • Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University
    Dec 13, 2023Inhibitor Therapeutics, Inc. (INTI) Press Releases
  • INHIBITOR Therapeutics Receives prostate cancer IND Clearance from FDA
    Jan 22, 2020Inhibitor Therapeutics, Inc. (INTI) Press Releases
  • INHIBITOR Therapeutics Submits Investigational New Drug Application for Treatment of Patients with Late-Stage Prostate Cancer
    Nov 25, 2019Inhibitor Therapeutics, Inc. (INTI) Press Releases
  • INHIBITOR Therapeutics Appoints Dr. Debra Peattie to its Board of Directors
    Oct 31, 2019Inhibitor Therapeutics, Inc. (INTI) Press Releases
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
$0.06Close ยท Sep 22, 2026